Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Osteosarcoma patients and Ewing sarcoma patients, this post can help you

What did Cabometix® demonstrate?

Two drugs, Cabometix® (Cabozantinib) and Stivarga® (Regorafenib) are approved for various indications and are now breakthroughs in the treatment of advanced stages of these two types of cancer.

Cabozantinib® has extended the life of some patients with advanced Osteosarcoma and some advanced Ewing Sarcoma patients who have already received several treatments for their disease and are unresectable and/or stage 4 metastatic.

The expected median survival rate of these patients, who underwent several treatments, is extremely bleak with the standard treatments.

Cabometix® demonstrated the highest and most impressive response rate known today among all (!) drugs that work in a similar mechanism of action that showed activity in sarcoma of the bones, according to the results of a study called CABONE, recently reported at the Connective Tissue Oncology Society, CTOS, Annual Meeting, which took place on 14-17 November 2018 in Rome, Italy.

Most of the side effects observed in the study were minimal.

Cabometix® is a drug taken orally and inhibits the c-MET, VEGFR-2 and AXL kinases in cancer cells.

Patients aged 12 years and older participated in CABONE, with patients under the age of 18 receiving the drug 40 mg/mm, and patients aged 18 and over received the same dose at 60 mg/mm daily in 28-day cycles. Over 90% of the study participants had metastatic disease, stage 4.

Dr. Catherine Jainaway, one of the world’s leading centers in the US, noted that another study called SARC024 showed similar results with another drug known as Stivarga® (Regorafenib)..

The current situation

Ewing sarcoma and Osteosarcoma, are the most common types of bone cancer among children and young adults.

There are currently no approved drugs for the treatment of unresectable and/or stage 4 metastatic patients.

The median survival expected for patients whose disease is back is less than 10 months with all the existing standard protocols.

Participating in clinical trials should be offered to patients at this stage with the aim of increasing the chances for better treatment outcomes.

In order to know if you are suitable for such advanced and groundbreaking treatments or for clinical trials with other innovative treatments and drugs, contact us and we will be happy to help.

TRIAL•IN Pharma provides a unique, personalized service for patients with metastatic cancer and brain tumors, which reveals innovative and advanced cancer treatments around the world and helps to achieve them.

Call us 24/7 toll free to find out if our services match your current medical and clinical condition:

+44.2082.426.039

or leave us a message on our website and we’ll get back to you shortly:

www.trial-in.com

TRIAL•IN Pharma – We do not give up on life!

For further reading

https://www.targetedonc.com/conference/ctos-2018/cabozantinib-prolongs-survival-in-patients-with-advanced-osteosarcoma-and-ewing-sarcoma?fbclid=IwAR0oELpxsaCLK2AwL9LAoKbvdhWblT5e_U692lJJFFxltrAve5rNUp_TjTw

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu